NCT06774625View on ClinicalTrials.gov

This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars

PHASE2CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 19, 2024

Primary Completion Date

August 8, 2025

Study Completion Date

August 8, 2025

Conditions
Acute Pain, Postoperative
Interventions
DRUG

LTG-001 High Dose

LTG-001 High Dose

DRUG

LTG-001 Mid Dose

LTG-001 Mid Dose

DRUG

LTG-001 Low Dose

LTG-001 Low Dose

OTHER

Placebo

Placebo

DRUG

Suzetrigine

Active comparator - Nav1.8 inhibitor

Trial Locations (1)

84107

JBR Clinical Research, Salt Lake City

Sponsors
All Listed Sponsors
lead

Latigo Biotherapeutics

INDUSTRY

NCT06774625 - This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars | Biotech Hunter | Biotech Hunter